Cancer Immunotherapy Market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during 2018-2025.
Portland, OR -- (SBWIRE) -- 05/17/2018 -- The report aims to offer a comprehensive strategic analysis of the global cancer immunotherapy market along with the revenue and growth forecast for the period, 2018-2025. It includes the market size, share analysis, market segmentation, market forecast, drivers, restraints & opportunities, and key market players along with their profiles. The report is carefully compiled after an extensive gathering of information from industry-centric organizations which has been further endorsed by industry leaders. Bringing out the key insights of the industry, the report caters to various stakeholders, including market players, investors, industry leaders, and others, who wish to understand the latest trends, current market scenario, and latest technologies used in the industry.
Request a sample report for cancer immunotherapy market:
The report provides information about the factors that drive or hamper the adoption of cancer immunotherapy. The market is driven by the rise in funding from various government and private organizations for carrying out R&D activities for cancer immunotherapy, growing occurrence of cancer globally, rise in approvals for the clinical trials and the growing acceptance of cancer immunotherapy are driving the demand of the industry. On the other hand, the high cost associated with cancer immunotherapy restrains the industry growth.
The report analyzes the global cancer immunotherapy market based on type, application, end user, and geography. Based on type, the market is classified into monoclonal antibodies, immunomodulators, cancer vaccines, and checkpoint inhibitors. The monoclonal antibodies segment is anticipated to grow at a CAGR of 14.79% during the forecast period. Based on application, the market is bifurcated into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, head and neck cancer, and others. The lung cancer segment is expected to garner $22,396.8 million while the breast cancer sector is likely to accrue a sum of $18,911.5 million by 2025. Based on end-user, the market is divided into hospitals, cancer research centers, and clinics. The hospitals sector is anticipated to reach $99,256.8 million by 2025. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. In North America, the market analysis is covered for the U.S., Canada, and Mexico. In Europe, the market analysis covers UK, Germany, France, Spain, Italy, and the rest of Europe. In Asia-Pacific, the market study covers the regions such as China, Japan, India, Australia, South Korea, and the rest of Asia-Pacific.
Get 20% Discount On Customization:
The report also includes the profiles of the leading players of the cancer immunotherapy market, including Novartis, AstraZeneca, Bristol-Myers Squibb, Amgen, F. Hoffman La-Roche, Eli Lilly and Company, Merck & Co., Inc., Janssen Global Services, LLC, Bayer AG, and Pfizer among others. The report discusses their product information, market size, market share, business strategies and much more to help analysis, investors and others interested in the market to take wise business decisions